271 results on '"Sculpher, Mark"'
Search Results
2. System-wide approaches to antimicrobial therapy and antimicrobial resistance in the UK: the AMR-X framework
3. Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required
4. Abstract 16635: Cost Effectiveness Analysis of the Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction REVIVED Trial Data
5. Percutaneous Revascularisation for Ischemic Left Ventricular Dysfunction: Cost-Effectiveness Analysis of the REVIVED-BCIS2 Trial
6. We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment
7. Global Health Economics
8. Supporting the Development of Health Benefits Packages (HBPs): Principles and Initial Assessment for Malawi
9. Cost-Effectiveness Thresholds: Guiding Health Care Spending for Population Health Improvement
10. Economic evaluation of self-help group interventions for health in LMICs: a scoping review
11. Using Age-Specific Values for Pediatric HRQoL in Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How?
12. Randomised trial of stable chest pain investigation: 3-year clinical and quality of life results from CE-MARC 2
13. A qualitative study on the feasibility and acceptability of institutionalizing health technology assessment in Malawi
14. Comparative cost-effectiveness of alternative imaging and surveillance schedules for testicular seminoma in the TRISST trial.
15. Developing a Modeling Framework for Quantifying the Health and Cost Implications of Antibiotic Resistance for Surgical Procedures
16. Assessing the potential of HTA to inform resource allocation decisions in low-income settings: The case of Malawi
17. Recommendations on Perspectives for the Reference Case
18. Designing a Cost-Effectiveness Analysis
19. Reflecting Uncertainty in Cost-Effectiveness Analysis
20. Theoretical Foundations of Cost-Effectiveness Analysis in Health and Medicine
21. Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates
22. Economic Evaluation of Health Care Programmes and Interventions: Applications to Low- and Middle-Income Countries
23. Using Economic Evaluation to Inform Responses to the Opioid Epidemic in the United States: Challenges and Suggestions for Future Research
24. A Qualitative Study on the Feasibility and Acceptability of Establishing Health Technology Assessment (HTA) in a Low Income Country Setting: The Case of Malawi
25. Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?
26. Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol
27. Estimating the global demand curve for a leishmaniasis vaccine: a generalisable approach based on global burden of disease estimates
28. Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems
29. Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies
30. Program Evaluation of Population- and System-Level Policies: Evidence for Decision Making
31. Health technology assessment in low- and middle-income countries: a case study of trastuzumab for early and locally advanced HER-2 positive breast cancer in Tunisia
32. Methodological issues in economic evaluations of emergency transport systems in low-income and middle-income countries
33. Authors’ Response to: “Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al.” by Sampson, Firth, and Towse
34. From impact evaluation to decision-analysis: assessing the extent and quality of evidence on ‘value for money’ in health impact evaluations in low- and middle-income countries
35. Ideas About Resourcing Health Care in the United States: Can Economic Evaluation Achieve Meaningful Use?
36. Modelling the health and economic impacts of different testing and tracing strategies for COVID-19 in the UK
37. Cost Effectiveness and Payment Policy
38. Economic evaluation of public health interventions
39. Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk
40. Cost-effectiveness of cardiovascular imaging for stable coronary heart disease
41. Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial
42. Economic analysis of the prevalence and clinical and economic burden of medication error in England
43. BACK MATTER
44. FRONT MATTER
45. The HOME Study: Statistical and economic analysis plan for a randomised controlled trial comparing the addition of Proactive Psychological Medicine to usual care, with usual care alone, on the time spent in hospital by older acute hospital inpatients
46. Health Opportunity Costs: Assessing the Implications of Uncertainty Using Elicitation Methods with Experts
47. Distributional cost effectiveness analysis of West Yorkshire low emission zone policies
48. Real‐world data on the incidence, mortality, and cost of ischaemic stroke and major bleeding events among non‐valvular atrial fibrillation patients in England
49. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
50. Modelling the Health and Economic Impacts of Population-Wide Testing, Contact Tracing and Isolation (PTTI) Strategies for COVID-19 in the UK
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.